Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10361732 | 0.87 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL5930306 | 0.82 | CDK1 (0.52) | HSP90AA1HSP90AB1SLC29A1CDK1CCNB1 | |
| SCHEMBL5930259 | 0.80 | HSP90AB1 (0.45) | HDAC6HSP90AA1HSP90AB1 | |
| SCHEMBL23710675 | 0.80 | ALDH1A1 (0.42) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL8781655 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL9187637 | 0.77 | KDM4E (0.37) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL4084012 | 0.76 | ADORA2A (0.56) | ALDH1A1HPGDLMNA | |
| SCHEMBL16111664 | 0.75 | CCNE1 (0.47) | SLC29A1CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL14010824 | 0.74 | KDM4E (0.55) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL10516011 | 0.72 | KDM4E (0.37) | KDM4EALDH1A1HPGDADRA1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | claimed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| US-5246937-A | Viricides, herpes simplex | BEECHAM GROUP P.L.C. (GB) | 1993-09-21 | — | — | US | claimed |
| EP-0182024-B1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | BEECHAM GROUP PLC (GB) | 1991-04-03 | — | — | EP | claimed |
| WO-1987005604-A1 | 2-AMINOPURINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BEECHAM GROUP P.L.C. (GB) | 1987-09-24 | — | — | WO | claimed |
| EP-0182024-A2 | Purine derivatives and their pharmaceutical use | BEECHAM GROUP PLC (GB) | 1986-05-28 | — | — | EP | claimed |
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | disclosed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2968228-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | Quadex Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | QUADEX PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC | 2015-12-03 | — | — | US | disclosed |
| US-9125911-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| WO-2014160369-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-5559114-A | Treatment of autoimmune disease using 2-amino purine derivatives | EXLEY RAY W (US) | 1996-09-24 | — | — | US | disclosed |
| WO-1996018397-A1 | THE TREATMENT OF AUTOIMMUNE DISEASE USING 2-AMINO PURINE DERIVATIVES | EXLEY RAY W (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5250688-A | Treating herpes virus infections | BEECHAM GROUP P.L.C. (GB) | 1993-10-05 | — | — | US | disclosed |
| US-5246937-A | Viricides, herpes simplex | BEECHAM GROUP P.L.C. (GB) | 1993-09-21 | — | — | US | disclosed |
| EP-0182024-B1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | BEECHAM GROUP PLC (GB) | 1991-04-03 | — | — | EP | disclosed |
| WO-1987005604-A1 | 2-AMINOPURINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BEECHAM GROUP P.L.C. (GB) | 1987-09-24 | — | — | WO | disclosed |
| EP-0182024-A2 | Purine derivatives and their pharmaceutical use | BEECHAM GROUP PLC (GB) | 1986-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | NT5E, SAMHD1, DCTD | KDM4E 2688/4885ALDH1A1 3897/4885HPGD 2762/4885 |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | SAMHD1, CUTA, TK1 | KDM4E 3024/4885ALDH1A1 4317/4885HPGD 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.